Cargando…

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder

BACKGROUND: This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder–inhaled antibiotic for Pseudomonas aeruginosa infection. METHODS: CF patients aged 6 years or older treated with at least...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenberg, Jonathan, Palmer, Jacqueline B, Chan, Wing W, Correia, Catherine E, Whalley, Diane, Shannon, Paul, Sawicki, Gregory S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087789/ https://www.ncbi.nlm.nih.gov/pubmed/27822017 http://dx.doi.org/10.2147/PPA.S102234

Ejemplares similares

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
por: Gauthier, Timothy P., et al.
Publicado: (2015)

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis
por: Vázquez-Espinosa, Emma, et al.
Publicado: (2015)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report
por: Santos, Roberto P, et al.
Publicado: (2007)

Unknown Renal Impairment: A Rare Case of Inhaled Tobramycin Induced Acute Kidney Injury in a Cystic Fibrosis Patient
por: Miller, Tyler, et al.
Publicado: (2021)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
por: Terpstra, Lotte C., et al.
Publicado: (2022)

Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis
por: Reverchon, Jérémy, et al.
Publicado: (2022)

Efficacy of inhaled tobramycin in severe nosocomial pneumonia
por: Kuzovlev, A, et al.
Publicado: (2012)

Inhaled tobramycin for the treatment of nosocomial pneumonia in sepsis
por: Kuzovlev, A, et al.
Publicado: (2014)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

Adherence with tobramycin inhaled solution and health care utilization
por: Briesacher, Becky A, et al.
Publicado: (2011)

Early preventive administration of inhaled tobramycin in severe polytrauma
por: Kuzovlev, A, et al.
Publicado: (2015)

Low Molecular Weight Chitosan-Coated PLGA Nanoparticles for Pulmonary Delivery of Tobramycin for Cystic Fibrosis
por: Al-Nemrawi, Nusaiba K., et al.
Publicado: (2018)

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
por: Deschamp, Ashley R, et al.
Publicado: (2017)

Once daily aerosolised tobramycin in adult patients with cystic fibrosis in the management of Pseudomonas aeruginosa chronic infection
por: Mantero, Marco, et al.
Publicado: (2017)

Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
por: Stehling, Florian, et al.
Publicado: (2017)

Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin
por: Muirhead, Corinne, et al.
Publicado: (2017)

Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem
por: Narayanaswamy, Vidya P., et al.
Publicado: (2017)

Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
por: Murphy, Ronan A., et al.
Publicado: (2022)

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
por: Wilson, Robert, et al.
Publicado: (2013)

Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device
por: Elkins, Mark R., et al.
Publicado: (2014)

Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study
por: Mainz, Jochen G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qg9ibccjrcjiu300k37cbp08ka